**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript NO: 11647**

**Columns: Topic Highlights**

WJG 20th Anniversary Special Issues (11): Cirrhosis

**Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis**

Giannelli V *et al.* Dysbiosis and gut-liver axis in cirrhosis

Valerio Giannelli, Vincenza Di Gregorio, Valerio Iebba, Michela Giusto, Serena Schippa, Manuela Merli, Ulrich Thalheimer

**Valerio Giannelli, Vincenza Di Gregorio, Michela Giusto, Manuela Merli,** Gastroenterology Department of Clinical Medicine, Sapienza University of Rome, 00185 Rome, Italy

**Valerio Iebba, Serena Schippa,** Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy

**Ulrich Thalheimer,** Liver Unit, Royal Devon and Exeter Foundation Trust, Exeter EX2 7JU, United Kingdom

**Author contributions:** Thalheimer U and Merli M have equally contributed as senior authors; all authors contributed in writing and revising the manuscript.

**Correspondence to: Manuela Merli, Professor,** Gastroenterology Department of Clinical Medicine, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185 Rome, Italy. manuela.merli@uniroma1.it

**Telephone:** +39-6-49972004 **Fax:** +39-6-4453319

**Received:** May 29, 2014**Revised:** July 26, 2014

**Accepted:**September 29, 2014

**Published online:**

**Abstract**

Liver disease is associated with qualitative and quantitative changes in the intestinal microbiota. In cirrhotic patients the alteration in gut microbiota is characterized by an overgrowth of potentially pathogenic bacteria (*i.e.* gram negative species) and a decrease in autochthonous familiae. Here we summarize the available literature on the risk of gut dysbiosis in liver cirrhosis and its clinical consequences. We therefore described the features of the complex interaction between gut microbiota and cirrhotic host, the so called "gut-liver axis", with a particular attention to the acquired risk of bacterial translocation, systemic inflammation and the relationship with systemic infections in the cirrhotic patient. Such knowledge might help to develop novel and innovative strategies for the prevention and therapy of gut dysbiosis and its complication in liver cirrhosis.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Dysbiosis; Cirrhosis; Bacterial translocation; Inflammation; Infection; Bacterial overgrowth; Rifaximine; Lactulose; Liver; Gut; Portal hypertension

**Core tip:** In this review we reported the most recent concepts on the complex interaction between gut microbiota and cirrhotic host, namely the gut-liver axis. We focused our attention to the clinical consequences of gut dysbiosis in cirrhosis such as the acquired risk of bacterial translocation, systemic inflammation and the relationship with systemic infections.

Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

The role of the gut microbiota in liver disease emerged in the middle of the last century with the recognition of the relationship between hepatic coma and the absorption of nitrogenous metabolites from the intestine[1]. This evidence was followed by the description of a disequilibrium in fecal bacterial composition, with a relative abundance of coliforms in the small intestine of cirrhotics[2]. A role of intestinal bacteria in the pathogenesis of hepatic encephalopathy (HE) has been supported by clinical studies, demonstrating that intestinal antibiotics and non-absorbable disaccharides led to improvement of HE[3]. The increased risk of gut dysbiosis due to liver cirrhosis was already foreseen in the 70's[4]. Since then many new studies have further defined and described the alteration of gut bacteria population in liver cirrhosis and its consequences, mainly due to the passage of bacteria (or bacterial products) towards the liver and systemic circulation *via* the portal circulation or lymphatic system. The growing attention in the last years to this issue, the so called "gut-liver axis", is explained by the fact that liver is in fact chronically exposed to gut-derived factors including bacteria and bacterial components. The passage of bacteria, or a part of them, has been recently associated with systemic inflammation and the complications of cirrhosis, such as hepatic encephalopathy[5] (Figure 1).

This review aims at describing the evolution on the understanding of gut microbiota in end-stage liver disease over the last decades, the development of techniques to study gut microbiota, the characterization of gut dysbiosis and the clinical consequences of it.

**Literature Research**

Bibliographic searches were performed in MEDLINE and EMBASE for the following words (all fields): (‘‘Gut Microbiota” or “Bacterial Translocation” or “Inflammation” or “dysbiosis” or “rifaximin” or “lactulose”) and (‘‘cirrhosis” [MeSH]) and (‘‘cirrhosis decompensation” [MeSH] or ‘‘hepatic encephalopathy” or “hyperdynamic circulation”). Other relevant trials were identified by hand searched of the reference lists of the clinical trials identified during the electronic search. A first review was performed on the abstracts of the articles selected and if the inclusion criteria were satisfied, articles were included in the analysis. The information extracted from each of the selected publications included study design details, patient and microbiota characteristics, animal models of dysbiosis, methods of gut bacterial investigation and clinical consequences of dysbiosis. Studies published in abstract form only, or in non-English language were excluded.

**Are we made of bacteria?**

The human intestinal tract harbors one of the most densely populated ecosystems on earth. The number of microorganisms living in the intestine range between 1014-1015 CFU/ml[6,7]. The gastrointestinal (GI) tract is the largest epithelial surface of the body and is in constant exposure to bacteria. More than 70% of all micro-organisms associated with the human body lives in the intestine, probably related to the richness of nutrients in this area. The total genome of microorganisms that are part of the flora, called microbiome (60000 genes), exceeds that encoded by the human genome by a factor of approximately 100, providing the expression of functions which have not evolved in humans[8]. We can therefore be considered a superorganism consisting of microbial and human cells, and our genome is the sum of our genes and those belonging to the billions of microorganisms that are part of our Microbiota[9]. The distribution of the micro-organisms varies from 10 to 102 bacteria/ml between stomach and duodenum, to 102 to 108 bacteria/ml between jejunum and ileum, culminating in 1012-1013 bacteria/ml in the colon[10]. Most bacteria of faecal origin belong to two major phylogenetic lineages: *Firmicutes* and *Bacteroidetes.* In minor proportion *Actinobacteria* and *Proteobacteria* are also present[11]. In healthy subjects, species belonging to these phyla live in peaceful coexistence[11]. In the last decade, several pathologies have been correlated to alterations in the intestinal ecosystem equilibrium- this is called dysbiosis. In such a condition there is an increase of potentially pathogenic bacteria species/groups [*Enterobacteriaceae, Escherichia coli* (*E. coli*)], instead of potentially beneficial bacterial species /groups [*Clostridiales, Faecalibacterium prausnitzi* (*F. prausnitzi*)]. *E. coli* is a commensalliving in the large intestine; several strains within this species, harboring a set of virulent genes, cause a wide range of diseases[12]. *F. prausnitzi* is copiously present in the human gut, and it is one of the main producers of butyrate, which is the energy source for cells of the colonic mucosa. A decrease in *Faecalibacteria* in adult patients has been associated with inflammatory bowel disease (IBD)[13,14]. Recently the ratio of *F. prausnitzi*/*E. coli* expressed as relative abundances, has been proposed as a possible indicator of intestinal dysbiosis in adult subjects[15].

***Gut microbiome in liver disease: stable component or changing companion***

A legitimate question arises when we begin to approach the gut microbiota in liver disease; is it the liver disease which modifies the gut bacteria or is it the gut dysbiosis which causes liver disease? Before answering these questions we need to discuss the stability of gut microbiota over time. The concept that the individual "fingerprint" of gut microbiota does not change within the host during his or her life is now under debate[16]. In their study Li *et al*[16] found a general microbiome signature conserved among body habitats of the same body region and over time suggesting that a relatively stable microbial community structure is maintained throughout the human microbiota. Analyses of the variation for the abundances of phila across the cohort reveal that the detected core taxa are also stable. However this observation changed when the attention was shifted to oral and stool habitats which, in contrast to the rest of the body, tended to vary over time[16].

It is also important to emphasize that a phylum-based analysis is not suitable in cirrhosis, especially since Firmicutes includes several pathogenic taxa such as Staphylococceae and Enterococcaceae, which indeed are over-abundant in the sickest population and are very different from its other constituents such as Lachospiraceae and Ruminococcaceae in their ultimate impact[17].

Indeed recent studies on gut microbiota in cirrhosis have shown that microbiota changed when the underlying disease worsened[18]. In advanced liver cirrhosis there appears to be an increase in dysbiosis, with a greater abundance of gram-negative taxa (Enterobacteriaceae, Bacteroidaceae). The consistent pattern of microbiota change and its association with the severity of cirrhosis cross-sectionally and longitudinally indicates that the underlying severity of cirrhosis may be a stronger determinant of microbial abundance. The influence of liver disease on gut bacteria composition is also confirmed by another study conducted in Asiatic cirrhotic hosts. Chen *et al*[19], by analyzing fecal samples of 36 cirrhotic patients and 24 healthy people, found that patients with cirrhosis had a reduced concentration of *Bacteroidetes* and *Lachnospiraceae*, whereas *Proteobacteria, Fusobacteria, Enterobacteriaceae, Veillonellaceae* and *Streptococcaceae* were increased. Interestingly, in their work the authors found that the alteration of microbiota composition correlated with the severity of liver disease.

But liver disease per se is not the only variable which could influence the gut microbiota. In fact, cirrhotics are frequently exposed to health care structures and hospital admissions, among patients with decompensated cirrhosis, are common. The increase of certain bacterial taxa related to hospitalization such as Propionibacteriaceae and Halomonadaceae have been recently identified as markers of the underlying abnormal intestinal milieu and these bacterial taxa have been described as potential pathogens in humans[20,21]. The use of antibiotics during hospitalization is also frequent and might interact with the composition of gut microbiota. In the study of Pérez-Cobas *et al*[22], in the first days of antibiotic treatment the majority of the microbiota included species from the phylum Firmicutesa. A drastic shift occurred 4-6 days after the start of antibiotic treatment (based on betalactam antibiotics), in fact, after one week of antibiotic therapy the predominantly active taxa were mainly members of the Streptococcaceae, Clostridiaceae and Bacteroidaceae (which are considered to belong to the "non autochthonous" group of bacteria)[5,18,23].

Dietary modifications may also affect the stability of gut microbiota in cirrhotic patients over time. For instance, restriction of dietary protein was considered a mainstay in the therapy of hepatic encephalopathy for a long time. More recently, it has been recognized that protein energy malnutrition is frequent in advanced liver disease and may adversely affect patient outcome[24]. So far there are no data on the effect of diet on gut microbiota in liver disease, however an interesting study comparing healthy subjects on a "western diet" with those on an high fiber diet with low protein and carbohydrate content, clearly showed changes in gut microbiota. De Filippo *et al*[25] compared the fecal microbiota of European children and that of children from a rural African village, where the diet washigh in fiber content and low in animal derived protein and carbohydrates.The author found significant differences in gut microbiota between the two groups. The group with a low protein and carbohydrate diet showed a significant enrichment in Bacteroidetes and a depletion in Firmicutes, with a unique abundance of bacteria from the genus Prevotella and Xylanibacter, known to contain a set of bacterial genes for cellulose and xylan hydrolysis, which was completely lacking in the subjects on a Western diet. Also, Enterobacteriaceae (Shigella and Escherichia) were significantly lower in the "Fiber-based diet" as opposed to the "protein and polysaccharide-rich diet"[25].

It is therefore possible that the gut microbiome is a changing companion, which coevolved with the host and varies also according to his health and diet.

***Liver-gut axis: microbiota modification in cirrhosis***

In the past, the description of the qualitative and quantitative characteristics of gut microflora composition in cirrhotic patients, has been limited by the scarce reliability of the culture techniques performed on fecal samples or on intestinal lumen aspirates. The advent of molecular techniques, mainly based on Polymerase Chain Reaction (PCR) of the bacterial ribosomal 16S rDNA sequence are now allowing to perform a complete description of the entire bacterial community of a sample. By means of techniques such as Temporal Temperature Gradient Gel Electrophoresis (TTGE), Real-time PCR and the recent pyrosequencing, it is becoming clear that patients suffering from chronic liver disease could harbor an unbalanced gut microbiota composition.

Cirrhotic patients are exposed to a higher risk of dysbiosis because of a variety of pathological interactions between the liver and the gastrointestinal tract. The alteration in intestinal motility, the higher gastric pH and the reduced bile acid concentration in the colon seen in patients with cirrhosis, may lead to a failure in the control of bacterial intestinal growth[26-28]. The clinical implications of this failure in the cirrhotic host might be represented by the occurrence of pathological bacterial translocation, a higher risk of intestinal bacterial infections and the risk of decompensation of liver disease[29].

When the gastric acid barrier fails (drug-induced hypochlorhydria, Helicobacter Pylori colonization, autoimmune atrophic gastritis, gastric surgery, *etc.*), “oropharyngeal flora” including mainly Gram-positive bacteria (Streptococcus spp., Staphylococcus spp., Micrococcus spp., Lactobacillus spp., Neisseria spp., Veillonella spp., Stomatococcus spp., Gemella spp., Corynebacterium spp., Actinomyces spp., Fusobacterium spp.) increases in the stomach, duodenum and proximal jejunum. At the same time, when the intestinal clearance is impaired (due to a reduction of small bowel motility), the concentration of the “colonic flora” (including Enterobacteriaceae, Enterococcus spp., Pseudomonas spp. and Bacteroides spp.) increases in the small intestine[30]. The pathogenesis of the decreased intestinal motility in cirrhotic patients is not completely clear, but is probably multifactorial: the main involved mechanism is the presence of an autonomic neuropathy[31] which contributes to a delayed oro-cecal transit time (OCTT)[32]. Moreover, frequent comorbidities, such as diabetes, and long term pharmacological therapies may also prolong the OCTT. Beta-blockers, by improving intestinal motility and bylowering intestinal permeability, may reduce the small intestinal bacterial overgrowth (SIBO) and decrease the rates of spontaneous bacterial peritonitis[33-35]. In addition, the decrease in bile acids entering the intestine appears to favor the overgrowth of pathogenic and pro-inflammatory members of the microbiome including Porphyromonadaceae and Enterobacteriaceae[36], in fact , due to the reduced concentration of bile acid, the bacterial population relying on 7α-dehydroxylation for their energy supply collapses[36].

Kakiyama *et al*[37] showed that dysbiosis in patients with cirrhosis is partially due to low bile acid excretion into the gut. The total amount of bile acids in feces of patients with advanced cirrhosis decreased roughly 5-fold compared to controls and the ratio of secondary versus primary biliary acid decreased significantly. The relative scarcity of secondary biliary acids significantly correlates with the reduction of the Clostridium cluster XIVa group; this is probably due to the high proportion of 7α-dehydroxylating bacteria within this cluster.

In animal models the production of secondary bile acids by this group of bacteria turned in a positive regulation of bile acid synthesis in the liver. In fact, the higher concentration of secondary bile acids in the ileum implies a lower concentration of tauro-β-muricholic acid, which is an inhibitor of hepatic bile acids synthesis (through the inhibition of FXR signaling)[38]. This interaction unveils another part of the complex interaction between gut microbiota and liver function. In this "liver-gut axis perspective", as the severity of cirrhosis progresses, less secondary bile acids reach the large bowel. In particular, among the secondary bile acids, deoxycholic acid (DCA) is the one which displays the most potent antimicrobial activity[39]. Thus, the consequence of its reduced concentration is a higher risk of bacterial overgrowth in the small bowel, often characterized by a reduced *F. prausnitzi*/*E. coli* ratio[23,40] because of the relative abundance of gram-negative members of the oral and gut microbiota.

The alteration of the immune response is another relevant player within this context. To date, very little is known about the intestinal immune system in patients with cirrhosis. It could be possible that in patients with cirrhosis a higher stimulation of Toll Like Receptors system occurs due to the higher exposure to pro-inflammatory cytokines such as TNF-a, but, despite the state of activation of mononuclear cells, the innate immune response does not seem to be as effective as in controls because of the reduced phagocytic and killing capacity[41].

***Liver-gut axis: quantitative changes of gut microbiota in cirrhosis***

Several studies have demonstrated that patients with cirrhosis frequently have a "quantitative" alteration of gut microbiota the so called small intestinal bacterial overgrowth, SIBO[30,42-44]. Therefore, in cirrhosis we have not only qualitative differences in microbial communities, compared with people without cirrhosis, but also an increased intestinal burden of bacteria. SIBO has been documented to correlate with the severity of liver disease and to be a risk factor for clinical decompensation of liver cirrhosis, due to the fact that it favors encephalopathy and spontaneous bacterial peritonitis (SBP)[45]. The pathological mechanism sustaining the correlation between SIBO and decompensation of cirrhosis is most likely bacterial translocation. As the reason for qualitative dysbiosis are multifactorial, also bacterial overgrowth is likely to be multifactorial including changes in intestinal motility, absence or decreased intestinal levels of bile acids, and altered mucosal innate immunity. Alteration in gastrointestinal motility in cirrhosis have been reported and ascribed to the effects of autonomic dysfunction, altered levels of neuropeptides and the effects of inflammatory mediators on bowel muscle and nerve[43]. The prevalence of SIBO, assessed by the quantification of the bacterial density in small intestinal aspirate, ranges from 30% to 73%[42,46-48]. In contrast, indirect estimates of SIBO obtained by glucose breath hydrogen test range from 30% to 49% because of the limited sensitivity of this test in the general population as well as in cirrhotic patients[48,49].

The methods used to analyze the presence of SIBO are still unsatisfying. In the last decade the diagnostic gold standard for SIBO was considered the microbiological culture of jejunal secretions. This test is the oldest method used to investigate the small intestinal gut flora. However, the invasive nature of this test and the belief that the cultures are often falsely negative because of the difficulties to cultivate obligate anaerobes, or falsely positive because of the possible contamination by the oral flora, led to the introduction of indirect, non-invasive substitutes.Hydrogen breath tests (HBT) are widely used to explore SIBO, however conclusions drawn from various studies are controversial: these tests seem to have some limitations, which may determine numerous types of bias particularly in cirrhotic patients.

HBTs are based on the fact that in humans the only source for hydrogen gas is the bacterial metabolism of carbohydrates.For these tests, different carbohydrates are orally administered to the patients and the concentration of hydrogen is measured in expired air before and after the administration of thechosen substrate[50]. Glucose and lactulose are the most commonly sugar used for diagnosis of SIBO.

The main limitation of glucose HBT is that the hydrogen peak can be due not only to bacterial overgrowth, but also to a slow intestinal transit, which can determine the presence of a residue of complex carbohydrates in the colon even after the usual 12 h fasting period; besides, an inadequate diet before the test may also influence the results (such as a diet rich in fiber). An example of the difficulties to use this test is given by Bauer *et al*[48] who demonstrated that in cirrhotic patients, the glucose HBT correlates poorly with the diagnostic gold standard for SIBO.

Lactulose is a carbohydrate which is not absorbed neither in the small intestine nor in the colon. The limitation of this test is that a rapid transit, which may be due also to the effect of the lactulose itself, is able to blunt a clear second peak making it impossible to distinguish SIBO from the physiologic colonic fermentation[50].

For these reasons, the sensibility and specificity for detecting SIBO of lactulose HBT are 68% and 44%, and for glucose HBT 62% and 83%, compared with jejunal cultures[50].

To date, these tests would need to be customized for the cirrhotic population and new methods to detect the quantitative and qualitative characteristics of gut microbiota should be derived by molecular biology (PCR, TTGE, Real-time PCR and pyrosequencing).

***Other factors to be taken into account: aetiology of liver disease and site of sampling***

In studies that have assessed the taxonomic composition of the intestinal microbiota in patients with cirrhosis due to different etiologies, the fecal microbial communities did not differ depending on the different aetiology of liver disease[18,51-54]. Therefore, it is conceivable that the condition of end-stage liver disease itself may determine the content of the intestinal microbiome. Some differences have however been reported by some studies, patients with alcoholic cirrhosis had a significantly higher abundance of Enterobacteriaceae and Halomonadaceae, lower abundance of Lachnospiraceae, Ruminococcaceae, and Clostridialies XIV, high endotoxin and lower *F. prausnitzii/E. coli ratio* despite statistically similar model for end-stage liver disease (MELD) score and BMI compared to cirrhotic patients of non alcoholic etiology. Whereas, in patients with cirrhosis due to nonalcoholic steatohepatitis (NASH), a higher abundance of Porphyromonadaceae, Bacterioidaceae, and lower Veillonellaceae was foundcompared to their non-NASH counterparts[18].

More recently, also the definition of dysbiosis based on qualitative and quantitative DNA analysis of stool specimens is under debate. In fact, studies in non-cirrhotic populations have demonstrated differences between the microbiome of the intestinal mucosa compared with the microbiome in the stool[55].

In the cirrhotic host one study have reported a significant difference in mucosa and stool’s bacteria composition[5]. Prominent bacterial genera found at a higher abundance in the mucosal microbiome belonged to Firmicutes (Blautia, Incertae Sedis XI), Actinobacteria (Propionibacterium and Streptomyces), and Proteobacteria (Vibrio). Interestingly most bacteria found in higher abundance in stool microbiome were Firmicutes (Leuconostoc, Roseburia, Veillonella, and Incertae Sedis XIV). Propionibacterium and Vibrio genera were significantly more abundant in the mucosa than in the stool.

In cirrhotic patients taking rifaximin or lactulose for HE, the stool microbiome did not show significant changes, by converse the mucosal microbiome in the rifaximin group showed a significantly decreased abundance of autochthonous bacteria (Blautia and Roseburia) and Veillonellaceae, but an increased abundance of Propionibacterium[56].

***Route of bacteria: from gut to liver***

The term bacterial translocation (BT) was first coined by Berg and Garlington in 1979 as the passage of viable bacteria from the gastrointestinal tract through the epithelial mucosa into the lamina propria and then to the mesenteric lymph nodes (MLN) and possibly other organs[57].

However this definition, along with the advances in DNA and microbiome-associated molecular patterns (MAMPs) detecting technology, has been expanded and BT is now defined as the migration of viable microorganisms but also of microbial products [endotoxins such as lipopolysaccharide (LPS), lipoteichoic acid, bacterial DNA, peptidoglycans, and fragments, *e.g.*, muramyldipeptide, *etc.*] across an anatomically intact intestinal barrier from the intestinal lumen to MLN and other extraintestinal organs and sites[58].

The mechanisms implicated in this phenomenon have not been completely clarifiedbecause of the difficulties to detect BT in humans. The data on the pathogenesis of BT are derived mainly from animal studies and, to date, only few studies have described it in healthy subjects and in pathological conditions.

Bacteria present in the autochthonous flora, in healthy people, are able to translocate in low numbers from the gut lumen, but are physiologically killed during their passage through the epithelial barrier or in the MLN, contributing to important immunological functions[59]. These events mean that MLN are normally sterile.In cirrhosis, alterations of physiological mechanisms may lead to translocation and replication of the endogenous gut flora in MLN[60]. The species that more frequently translocate are Enterobacteriaceae, Enterococcus spp and Proteus spp. On the other hand, obligate anaerobes are rarely able to cross the gastrointestinal barrier[61]. In some cases, the translocation of viable bacteria may induce “spontaneous” bacterial infections while the translocation of bacterial fragments may produce a pro-inflammatory state due to the release of cytokines and nitric oxide. It has been suggested that only BT with clinical consequences might be defined as “pathological”[29]. The growing attention to this phenomenon is motivated by the high impact of BT in terms of its frequency and its clinical consequences. The presence of enteric-derived bacteria in mesenteric lymph nodes and in the venous blood stream occurs more frequently in patient with cirrhosis compared with controls, and among cirrhotic patients BT is approximately 5-6 folds more frequent in Child C compared to Child A and B. Cirera *et al*[62], based on the culture of mesenteric lymph node in one hundred cirrhotic patients undergoing liver transplantation and in thirthy-five patients without cirrhosis undergoing laparatomy, found that enteric-derived bacteria were grown in approximately 8.1% Child B and in 31% Child C patients. Mesenteric lymph nodes of controls without cirrhosis were positive for bacterial growth in 8% of cases. Although the methodology of bacterial-culture used by Cirera *et al*[62] is now replaced by PCR technology because of its higher sensibility in detecting BT, their study has the value of firstly demonstrated two important issues in liver cirrhosis: (1) the rate and degree of pathological BT depend on the severity of liver disease; and (2) the translocation of entire and vital bacteria to MLN is a feature of the decompensated cirrhosis. On the contrary, if we consider the translocation of non-vital gut-derived bacteria (such as bacterial DNA or LPS) the scenario is rather different. In fact, this latter variant of translocation has been demonstrated to occur also in non ascitic mice and the detection of bacterial DNA in the systemic circulation and/or in the mesenteric lymph node seems to be independent fromthe severity of liver disease[63].

Current data suggest two major pathways of gastrointestinal permeability, which might contribute to translocation: transcellular, through the enterocytes, under the control of specific enterocyte channels and membrane pumps, and paracellular *via* the tight junctions holding epithelial cells together. More commonly, translocation generally occurs transcellularly and directly[29]. This route is more important than the paracellular route, as it can happen also in an intestine with a healthy mucosa. In the same way, there are two major routes by which bacterial compounds might gain access to the systemic circulation: *via* the enteric venous system to the portal vein or following the enteric lymphatic drainage[59]. Convincing evidence suggests that the lymphatic route might be the principal pathway of translocation. Experimental and clinical studies detected viable bacteria in MLN. Animal studies demonstrated the MLN are the first station where translocated bacteria can be found[59,64,65]. The identification of intestinal bacteria in normally sterile MLN is considered direct evidence of BT. As indirect marker, any detection of intestinal bacteria in cultures of the portal or peripheral blood may suggest BT, as well as the detection of endotoxin in peripheral blood. More recent methods involving PCR have been introduced for detecting microbial DNA in blood; these methods have a higher sensitivity than blood cultures for assessing BT[66].

Another limiting aspect of many studies coming from the last decades is represented by the use of cultures of the MLN to investigate this phenomenon: the presence of cultivable microorganisms in the MLN was considered proof of BT. This assumption implicates an underestimation of the possibility to translocate for the bacteria which are "difficult to culture", such as the anaerobic bacteria.

Because of the invasiveness to obtain MLN in human subjects, these techniques are seldom employed in studying BT in humans. Bacteria more frequently present in experimental models of BT, such as Enterobacteriaceae, are present in human MLN in only 25% of cases[62]. However, more recent studies applying PCR detection of bacterial human DNA found that about 40% of patients with advanced cirrhosis had pathological BT[67].

This percentage is similar to that reported previously[63]and is also similar to the percentage of cirrhotic patients having a positive serum level of LPS and lipopolysaccharide-binding protein[68]. More interestingly, the origin of the detected bacterial DNA is that typical of bacteria that usually are reported to cause episodes of infection, such as SBP.

Pathological factors leading to BT in cirrhotic patients are SIBO, increased intestinal permeability and alterations of the local host immune system. Bacterial overgrowth is probably a prerequisite for the development of BT; in cirrhotic rats the absence of SIBO prevents the development of BT and cirrhotic animals without BT had a similar count of cecal aerobic bacteria as healthy rats[44]. Indeed, bacteria that translocate to MLN are the same ones overgrowing in the intestinal lumen, although not all the bacteria present in large quantity are found in MLN[44,69,70]. These data suggest that other important factors are involved in BT.

The intestinal mucosal barrier has secretory and anatomical means of preventing the adhesion and penetration of microorganisms. Increases in intestinal permeability (IP) in patients with cirrhosis have been reported using various methods, and involving the assessment of structural changes, oxidative stress, and alteration in enterocyte function[63,71]. If the epithelium is not physically damaged, endogenous bacteria translocate by an intracellular route through the epithelial lining cells and then travel *via* the lymph to the mesenteric lymph nodes. If the epithelium is physically damaged, bacteria translocate *via* the intercellular route between the epithelial cells to directly access the blood and lymph nodes[59]. The increasing interest in intestinal permeability derives from the hypothesis that a leaky gut may lead to the passage of toxins, antigens, or bacteria into the body[72], and may play a pathogenetic role in the development of chronic liver injury[73]. Some studies have shown an association between increased intestinal permeability and severity of cirrhosis[72,73]. Nevertheless, an increased IP alone is not able to determine pathological BT; in an experimental model, Pérez-Paramo *et al*[65] showed that BT occured only in rats with associated SIBO and increased IP, whereas it did not occur in rats with either increased IP or SIBO.

Both systemic and local immune defenses are impaired in cirrhosis[74]. Gut microbiota interact with both the innate and the adaptive immune system. Cross talk between the mucosal immune system and the endogenous microflora favours the mutual growth, survival and inflammatory control of the intestinal ecosystem[75].

In cirrhosis, the impairment of the immune system may affect BT in two ways: the impairment of the local immune system (the gut associated lymphoid tissue) increases the ability of bacteria to translocate to MLN, the impairment of the adaptive immune system affects the capability of these microorganism to replicate and reach the systemic circulation, therefore causing the pathological consequences of BT.

In addition, impaired antimicrobial mechanisms may further contribute to the development of bacterial translocation in cirrhosis. In a recent study performed on rats, Teltschik *et al*[76] found that bacterial translocation was detectable in 40% of rats with cirrhosis. Compared with the group without translocation, these animals exhibited diminished intestinal Paneth cell producer antimicrobial factors (α-cryptdin 5 and 7 expression). In contrast, animals with portal vein ligation without cirrhosis had no alteration in antimicrobial peptides expression. The decrease in Paneth cell antimicrobial protein expression was most pronounced in the ileum and the caecum. According with these results, in cirrhotic rats the antimicrobial activity toward different commensal strains was reduced, especially in the distal ileum and the cecum[76], where most of the bacterial translocation it is thought to occur.

***Clinical consequences of changes in the intestinal microbiome***

The growing attention to the role of the gut microbiome in cirrhosis is justified by its key role in bacterial translocation[29], and by the role of this and other bacterial products such as endotoxin in the pathogenesis of complications of cirrhosis, including hepatic encephalopathy (HE), SBP, and other infections[66]. The inflammatory response secondary to the higher levels of circulating bacteria or microbiome-associated molecular patterns (MAMP) is among the leading causes of multi-organ failure, acute- on-chronic liver failure (ACLF), and death in cirrhosis[77]. In table 1 we summarize the clinical consequences of dysbiosis in the cirrhotic host.

**Dysbiosis and infection:** In hospitalized cirrhotic patients with nosocomial SBP, Gram-positive pathogens are the main isolated species (70% of all isolates), with methicillin-resistant *Staphylococcus aureus* in almost 25% of cases[78].

In two recent studies performed on cirrhotic patients, the authors found an increased abundance of members of the *Enterobacteriacae* family[51], which includes important Gram-negative pathogens such as *Salmonella*, *Shigella, Yersinia, Klebsiella* and *Escherichia coli*. Interestingly, the abovementioned species, especially *E. coli*, are those that most frequently cause infections and spontaneous bacteremia in patients with cirrhosis[79].

There are few data on the role of dysbiosis as a risk factor for the development of infections. However, a significantly preponderance of gram negative species has been found in stool samples from cirrhotic patients with SIRS[80]. Within this group a lower ratio of *F. prausnitzii*/*E. coli* and higher endotoxin levels have been found compared with cirrhotics without SIRS[80]. Also, in patients who developed SIRS and/or died from ACLF, endotoxin levels were higher and the microbiota ratio was lower with a significantly higher abundance of gram negative species[18,80]. It is conceivable that the reduction in autochthonous taxa can be deleterious for the intestinal mucosa given that they produce short-chain fatty acids which reduce colonic inflammation and nourish colonocytes, compete with pathogenic bacteria for nutrients, produce anti-bacterial peptides and may improve the intestinal barrier[81]. Therefore, the gut dysbiosis seems to participate in the disruption of intestinal epithelial tight junctions and the imbalance of proliferation and apoptosis of intestinal epithelial cells[81]. The resulting intestinal mucosal atrophy and edema associated with portal hypertension[82] might explain the higher concentration of serum endotoxin, which has been demonstrated in cirrhotic patients with dysbiosis.

**Bacterial translocation and infection in cirrhosis:** In addition to the potential of BT on the natural history of cirrhosis, another point of interest is represented by the higher risk of developing infections in patients once bacteria (or parts of bacteria) translocate to mesenteric lymphnodes and the systemic circulation. Animal studies demonstrate that the prevalence of bacterial translocation in animals with SBP is twice higher than in those without SBP (80% of BT *vs* 40%)[83]. The concept of bacterial translocation predisposing to infection in experimental cirrhosis is further supported by data showing that bacteria isolated from mesenteric lymph nodes are genetically identical to strains causing SBP in the same animal[64]. In a recent study, almost 20% of cirrhotic patients were found to have positive mesenteric lymph node cultures following partial hepatectomy, with bacteria responsible of post-operative infections being the same as those recovered from mesenteric lymph nodes in most cases[84].

Whether the qualitative composition of the intestinal microbiota represent a risk factor forinfection in cirrhotic patientshas not been completely clarified. The higher preponderance in cirrhotic stool and intestinal mucosa of those species of gram negative and positive bacteria (*Enterobacteriaceae*, *Streptococcus* spp. and *Enterococcus faecalis)*[5,18] that are most widely involved in systemic infections, along with the loss of non pathogenic commensal bacteria, suggest a critical interaction of intestinal dysbiosis and risk of infection in cirrhosis.

**Dysbiosis and inflammation:** There is another clinically relevant consequences of gut bacteria dysbiosis and overgrowth which is the induction of inflammation with hemodynamic derangement caused by migration of intestinal bacteria into the peritoneal cavity and the systemic circulation[66].

Inflammatory cytokines contribute to the development and maintenance of the hyperdynamic circulation, which worsen portal hypertension[43] in impairs liver function, contributing to the impairment of coagulation[27]. A causal relationship between BT-mediated inflammation and portal hypertension has been demonstrated in studies performed on animal models where the administration of bacterial DNA or LPS leads to exacerbation of portal hypertension[85]. Steib *et al*[85] infused LPS in the peritoneum of rats with bile duct ligation-induced cirrhosis and in sham-operate rats and found, after 3 h from infusion, an increased basal portal pressure only in fibrotic animals. They also found that, in cirrhotic rats, the LPS pretreatment after 3 h further up-regulated the expression of the pro-inflammatory pathway driven by TLR4 system and by MyD88. With this regard, it is interesting to report the results of a recent trial performed on cirrhotic patients, which were randomly assigned to receive a selective intestinal decontamination with norfloxacin (400 mg twice daily) or placebo[86]. In the treated arm, the serum endotoxin levels were significantly reduced after 4 weeks and only in these antibiotic-treated patients the authors demonstrated an amelioration of the hyperdynamic circulation compared with controls receiving placebo. This group of patients showed a reduced cardiac output and a reduced mean HVPG equal to 4 mmHg, whereas no effects were found on renal function (the glomerular filtration rate and the renin–angiotensin system did not change significantly after selective intestinal decontamination). These results in cirrhotic patients seem to indirectly demonstrate the vicious cycle existing between gut-dysbiosis, the pro-inflammatory state driven by bacterial translocation and the worsening of portal hypertension. The ability of norfloxacin to selectively alter the microbiota of the intestine could be responsible for the hemodynamic changes seen in these patients. Norfloxacin is incompletely absorbed from the intestine, is mostly active against aerobic gram-negative bacteria and rarely causes bacterial resistance.

In another recent study, the investigation was focused on the non-absorbable antibiotic rifaximin, and the authors found similar results to norfloxacin. In fact, treated mice with rifaximin had a reduction of portal pressure and fibrosis in vivo compared to the untreated group. This agent is concentrated in the gastrointestinal tract, thereby modulates the gram negative flora and reduces the production of intestinal bacteria-derived LPS with no systemic toxicity or resistance. In their elegant study,Zhu *et al*[87] went further in their analysis of mechanism of rifaximin on portal hypertension and inflammatory amelioration.

Since TLR4 is the canonical receptor for LPS, they used TLR4 mutant mice which were therefore unable to activate the TLR4 pathway in response to LPS presentation. In these TLR4 mutant animals, the exposure to LPS was not reflected by any change in portal hypertension, angiogenesis, fibrosis, and pro-inflammatory state even without rifaximin[87]. The TLR4 mutant mice showed comparable and, in some cases, less portal hypertension and inflammation than wild type cirrhotic mice who received rifaximin. Together, these data suggest that the beneficial effect of rifaximin on liver inflammatory state and portal hypertension are also mediated by the down regulation of the LPS-TLR4 pathway as a result of the reduced gram negative flora.

Rifaximin is of topical interest since it is FDA approved for treatment of hepatic encephalopathy, with an acceptable safety profile in patients with chronic liver disease. Therefore, the modulation of the microbiota might represent a potential therapeutic strategy in the management of liver disease. Intestinal decontamination with nonabsorbable antibiotics (*i.e.*, rifaximin) is also an effective treatment for minimal and overt hepatic encephalopathy[88,89].

In this scenario, recent studies have utilized a simple ratio of ‘‘good vs. bad’’(Firmicutes/Bacteroides) taxa abundance (termed the cirrhosis dysbiosis ratio) to identify patients at higher risk of cirrhosis complications. This ratio is based on prior studies in patients with cirrhosis, which includes the highly relevant taxon Enterobacteriaceae, which is important in complications of cirrhosis, and produces one of the most potent endotoxins[18].

Interestingly, Bajaj *et al*[18] found that patients with cirrhosis developed clinical decompensation (such as hepatic encephalopathy) more frequently in the presence of a relatively reduced abundance of taxa considered benign and autochthonous, including Lachnospiraceae, Ruminococcaceae, and Clostridialies Incertae Sedis XIV (from now on called Clostridialies XIV) and a relatively higher abundance of others, particularly Enterobacteriaceae and Bacteroidaceae[18,23]. Moreover they demonstrated again how the severity of liver disease *per se* negatively affects the composition of the microbiota; in fact the MELD score seemed to negatively correlated with *"*positive*"* bacteria such as Clostridiales XIV, Lachnospiraceae and Ruminococcaceae and with Rikenellaceae, and positively with potentially pathogenic taxa such as Staphylococcae, Enterococceae and Enterobacteriaceae. It is interesting to note that the "quality" of gut microbiota reflected the "quantity" of serum levels of endotoxin. In fact, in patients with lower concentration of faecal Clostridiales XIV, Lachnospiraceae and Ruminococcaceae, the levels of endotoxin were significantly higher. Among other species of interest, they also found a reduction in Veillonellaceae and Porphyromonadaceae with worsening liver disease compared to healthy controls. Considering the ratio between autochthonous and pathogenic bacteria (Firmicutes/Bacteroides), this was about three times higher in controls compared to all cirrhotic patients.

The liver is the first extraintestinal organ encountered by the venous blood from the small and large intestines draining from the portal vein. For this reason, the liver is vulnerable to the exposure of bacterial products translocated from the gut lumen *via* the portal vein. In a healthy organism only minor quantities of translocated bacterial products reach the liver. In general, the hepatic immune system tolerates these bacterial products avoiding an uncontrolled immune responses, a phenomenon known as “liver tolerance”[90]. The first immunological response to the presence of bacteria (or MAMPs) is driven by theactivation of innate immune system. In particular, translocated bacterial products augment the activation of hepatic immune cells through pattern recognition receptors including Toll-like receptors (TLRs). The activated TLR system induces the production of cytokinesuch as IL-1 and IL-6 and type I IFN. In recent studies, this kind of inflammation without infection has been defined as sterile inflammation and is caused by the release from damaged cells or tissues of some factors, such as alarmin, which trigger TLR signaling[91]. TLR system is a complex system which involves more than 10 members of the TLR family but the description of this intricate response is indeed outs of our review purposed[92,93]. It is however of interest to mention the role of TLR4 (which binds lipopolysaccharide) because its single nucleotide polymorphism (SNP) seems to correlate to the risk of liver cirrhosis in patients with chronic hepatitis C infection[94].

In two different study performed on animal models using mice knockout for TLR4 co-receptors (*i.e.*, CD14 and LPS-binding protein), the authors found a lower induction of liver fibrosis mediated by bile duct ligation[95,96]. Their results showed that TLR4-mutant mice have similar levels of elevated LPS in the blood compared to wild-type mice but a lowerliver fibrosis[97]. In addition, in another experience mice deficient of the TLR4, LPS binding protein and CD14 are shown to be resistant to alcohol-induced liver diseases[97,98]. Finally, gut sterilization with antibiotics decreased plasma LPS levels and liver steatosis, inflammation and injury after chronic ethanol exposure[99].

The potential therapeutics options are fascinating because they might allow the possibility to interrupt the vicious cycle existing between gut dysbiosis and liver disease. To date, relative small randomized controlled trials have been addressed to evaluate the effects of gut flora manipulation in patient with cirrhosis. In table 2 we summarize the most relevant studies, with greater attention to those aimed at verifying the clinical benefits of gut microflora modification. Overall, they agree with the result that targeting the gut microbiota might be effective in reducing the proliferation of harmful gut flora and consequently it limited the complications of dysbiosis such as the pathological bacterial translocation.

In these previous studies, the "manipulation" of gut bacteria has been done by prebiotics (*i.e.*, dietary manipulation/supplementation), probiotics and systemic or poor absorbable antibiotics. We do not consider the microbiota transplant because there are no data in cirrhotic patients, so far. On the whole, these studies demonstrated the positive effect of microbiota modulation in term of reduction of:fibrogenesis, endotoxin plasma concentration, portal hypertension and pro inflammatory state[56,68,100,101]. There is however still a lacking of data regarding the effect of these interventions on the specific gut bacteria composition in liver cirrhosis, with the exception of the recent studies conducted by Bajaj *et al*[102], which accurately studied the composition of microbiota after lactulose and/or rifaximin therapies. To date, the strongest evidence regarding the clinical benefit of gut modulation in cirrhosis is still based on the large literature on hepatic encephalopathy treatment, and rifaximin plus lactulose resulted to be superior to placebo in treating the overt and minimal hepatic encephalopathy. With this regard we refer the reader to the already published studies which extensively described this clinically relevant aspect of gut-liver axis[102,103].

**CONCLUSION**

We have reviewed the large literature supporting the concept of the strict interplay between gut bacteria and liver disease. Gut microbiota alteration turn to be rather common in advanced liver disease and it sustains the concept of how gut microbiota phenotype and the presence of pathological bacterial translocation are determinant factors for liver function and hepatic chronic inflammation. Herein, we also described the relevance of the clinical consequences of microbiota alteration. The clinical implications of dysbiosis required that future therapeutic approaches to liver cirrhosis, especially in decompensated patients, should consider the gut-liver axis.

**REFERENCES**

1 **Phillips GB**, Schwartz R, Gabuzda GJ, Davidson CS. The syndrome of impending hepatic coma in patients with cirrhosis of the liver given certain nitrogenous substances. *N Engl J Med* 1952; **247**: 239-246 [PMID: 14947933 DOI: 10.1056/NEJM195208142470703]

2 **Martini GA**, Phear EA, Ruebner B, Sherlock S. The bacterial content of the small intestine in normal and cirrhotic subjects: relation to methionine toxicity. *Clin Sci* (Lond) 1957; **16**: 35-51 [PMID: 13414138]

3 **Riggio O**, Varriale M, Testore GP, Di Rosa R, Di Rosa E, Merli M, Romiti A, Candiani C, Capocaccia L. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. *J Clin Gastroenterol* 1990; **12**: 433-436 [PMID: 2398251 DOI: 10.1097/00004836-199008000-00016]

4 **Thomas HC**, McSween RN, White RG. Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. *Lancet* 1973; **1**: 1288-1291 [PMID: 4126078 DOI: 10.1016/S0140-6736(73)91300-7]

5 **Bajaj JS**, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. *Am J Physiol Gastrointest Liver Physiol* 2012; **303**: G675-G685 [PMID: 22821944 DOI: 10.1152/ajpgi.00152.2012]

6 **Sekirov I**, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. *Physiol Rev* 2010; **90**: 859-904 [PMID: 20664075 DOI: 10.1152/physrev.00045.2009]

7 **Peterson DA**, Frank DN, Pace NR, Gordon JI. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. *Cell Host Microbe* 2008; **3**: 417-427 [PMID: 18541218 DOI: 10.1016/j.chom.2008.05.001]

8 **Bäckhed F**, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. *Science* 2005; **307**: 1915-1920 [PMID: 15790844 DOI: 10.1126/science.1104816]

9 **Burcelin R**, Serino M, Chabo C, Garidou L, Pomié C, Courtney M, Amar J, Bouloumié A. Metagenome and metabolism: the tissue microbiota hypothesis. *Diabetes Obes Metab* 2013; **15** Suppl 3: 61-70 [PMID: 24003922 DOI: 10.1111/dom.12157]

10 **Sartor RB**. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008; **134**: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]

11 **Arumugam M**, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human gut microbiome. *Nature* 2011; **473**: 174-180 [PMID: 21508958 DOI: 10.1038/nature09944]

12 **Kaper JB**, Nataro JP, Mobley HL. Pathogenic Escherichia coli. *Nat Rev Microbiol* 2004; **2**: 123-140 [PMID: 15040260 DOI: 10.1038/nrmicro818]

13 **Sokol H**, Lay C, Seksik P, Tannock GW. Analysis of bacterial bowel communities of IBD patients: what has it revealed? *Inflamm Bowel Dis* 2008; **14**: 858-867 [PMID: 18275077 DOI: 10.1002/ibd.20392]

14 **Takaishi H**, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. *Int J Med Microbiol* 2008; **298**: 463-472 [PMID: 17897884 DOI: 10.1016/j.ijmm.2007.07.016]

15 **Schippa S**, Iebba V, Santangelo F, Gagliardi A, De Biase RV, Stamato A, Bertasi S, Lucarelli M, Conte MP, Quattrucci S. Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients. *PLoS One* 2013; **8**: e61176 [PMID: 23613805 DOI: 10.1371/journal.pone.0061176]

16 **Li K**, Bihan M, Methé BA. Analyses of the stability and core taxonomic memberships of the human microbiome. *PLoS One* 2013; **8**: e63139 [PMID: 23671663 DOI: 10.1371/journal.pone.0063139]

17 **Goel A**, Gupta M, Aggarwal R. Gut microbiota and liver disease. *J Gastroenterol Hepatol* 2014; **29**: 1139-1148 [PMID: 24547986 DOI: 10.1111/jgh.12556]

18 **Bajaj JS**, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. *J Hepatol* 2014; **60**: 940-947 [PMID: 24374295 DOI: 10.1016/j.jhep.2013.12.019]

19 **Chen Y**, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L. Characterization of fecal microbial communities in patients with liver cirrhosis. *Hepatology* 2011; **54**: 562-572 [PMID: 21574172 DOI: 10.1002/hep.24423]

20 **Park HJ**, Na S, Park SY, Moon SM, Cho OH, Park KH, Chong YP, Kim SH, Lee SO, Kim YS, Woo JH, Kim MN, Choi SH. Clinical significance of Propionibacterium acnes recovered from blood cultures: analysis of 524 episodes. *J Clin Microbiol* 2011; **49**: 1598-1601 [PMID: 21325550 DOI: 10.1128/JCM.01842-10]

21 **Stevens DA**, Kim KK, Johnson N, Lee JS, Hamilton JR. Halomonas johnsoniae: review of a medically underappreciated genus of growing human importance. *Am J Med Sci* 2013; **345**: 335-338 [PMID: 22814360 DOI: 10.1097/MAJ.0b013e31825600de]

22 **Pérez-Cobas AE**, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, Otto W, Rojo D, Bargiela R, von Bergen M, Neulinger SC, Däumer C, Heinsen FA, Latorre A, Barbas C, Seifert J, dos Santos VM, Ott SJ, Ferrer M, Moya A. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. *Gut* 2013; **62**: 1591-1601 [PMID: 23236009 DOI: 10.1136/gutjnl-2012-303184]

23 **Bajaj JS**, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, Gillevet PM. Linkage of gut microbiome with cognition in hepatic encephalopathy. *Am J Physiol Gastrointest Liver Physiol* 2012; **302**: G168-G175 [PMID: 21940902 DOI: 10.1152/ajpgi.00190.2011]

24 **Merli M**, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V, Lattanzi B, Riggio O. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. *Metab Brain Dis* 2013; **28**: 281-284 [PMID: 23224378 DOI: 10.1007/s11011-012-9365-z]

25 **De Filippo C**, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci USA* 2010; **107**: 14691-14696 [PMID: 20679230 DOI: 10.1073/pnas.1005963107]

26 **Quigley EM**, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. *J Hepatol* 2013; **58**: 1020-1027 [PMID: 23183530 DOI: 10.1016/j.jhep.2012.11.023]

27 **Thalheimer U**, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. *Gut* 2005; **54**: 556-563 [PMID: 15753544 DOI: 10.1136/gut.2004.048181]

28 **Thalheimer U**, De Iorio F, Capra F, del Mar Lleo M, Zuliani V, Ghidini V, Tafi MC, Caburlotto G, Gennari M, Burroughs AK, Vantini I. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. *Eur J Gastroenterol Hepatol* 2010; **22**: 1228-1234 [PMID: 20512041 DOI: 10.1097/MEG.0b013e32833b4b03]

29 **Wiest R**, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. *J Hepatol* 2014; **60**: 197-209 [PMID: 23993913 DOI: 10.1016/j.jhep.2013.07.044]

30 **Bauer TM**, Steinbrückner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, Pelz K, Kist M, Blum HE. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. *Am J Gastroenterol* 2001; **96**: 2962-2967 [PMID: 11693333 DOI: 10.1111/j.1572-0241.2001.04668.x]

31 **Hendrickse MT**, Thuluvath PJ, Triger DR. Natural history of autonomic neuropathy in chronic liver disease. *Lancet* 1992; **339**: 1462-1464 [PMID: 1351136 DOI: 10.1016/0140-6736(92)92042-E]

32 **Maheshwari A**, Thuluvath PJ. Autonomic neuropathy may be associated with delayed orocaecal transit time in patients with cirrhosis. *Auton Neurosci* 2005; **118**: 135-139 [PMID: 15795187 DOI: 10.1016/j.autneu.2005.02.003]

33 **Senzolo M**, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. *Liver Int* 2009; **29**: 1189-1193 [PMID: 19508620 DOI: 10.1111/j.1478-3231.2009.02038.x]

34 **Lo GH**, Chen WC, Lin CK, Tsai WL, Chan HH, Chen TA, Yu HC, Hsu PI, Lai KH. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. *Hepatology* 2008; **48**: 580-587 [PMID: 18666235 DOI: 10.1002/hep.22358]

35 **Merli M**, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, Riggio O, Venditti M. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. *Liver Int* 2014; Epub ahead of print [PMID: 24836902 DOI: 10.1111/liv.12593]

36 **Ridlon JM**, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. *Gut Microbes* 2013; **4**: 382-387 [PMID: 23851335 DOI: 10.4161/gmic.25723]

37 **Kakiyama G**, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. *J Hepatol* 2013; **58**: 949-955 [PMID: 23333527 DOI: 10.1016/j.jhep.2013.01.003]

38 **Sayin SI**, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metab* 2013; **17**: 225-235 [PMID: 23395169 DOI: 10.1016/j.cmet.2013.01.003]

39 **Begley M**, Gahan CG, Hill C. The interaction between bacteria and bile. *FEMS Microbiol Rev* 2005; **29**: 625-651 [PMID: 16102595 DOI: 10.1016/j.femsre.2004.09.003]

40 **Quigley EM**. New perspectives on the role of the intestinal flora in health and disease. *J Gastrointestin Liver Dis* 2006; **15**: 109-110 [PMID: 16802003]

41 **Wiest R**, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. *Hepatology* 2005; **41**: 422-433 [PMID: 15723320 DOI: 10.1002/hep.20632]

42 **Bauer TM**, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. *Am J Gastroenterol* 2002; **97**: 2364-2370 [PMID: 12358257 DOI: 10.1111/j.1572-0241.2002.05791.x]

43 **Quigley EM**. Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited. *Dig Dis Sci* 1996; **41**: 557-561 [PMID: 8617136 DOI: 10.1007/BF02282341]

44 **Guarner C**, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. *J Hepatol* 1997; **26**: 1372-1378 [PMID: 9210626 DOI: 10.1016/S0168-8278(97)80474-6]

45 **Gupta A**, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. *J Hepatol* 2010; **53**: 849-855 [PMID: 20675008 DOI: 10.1016/j.jhep.2010.05.017]

46 **Morencos FC**, de las Heras Castaño G, Martín Ramos L, López Arias MJ, Ledesma F, Pons Romero F. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. *Dig Dis Sci* 1995; **40**: 1252-1256 [PMID: 7781442 DOI: 10.1007/BF02065533]

47 **Pardo A**, Bartolí R, Lorenzo-Zúñiga V, Planas R, Viñado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull MA. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. *Hepatology* 2000; **31**: 858-863 [PMID: 10733540 DOI: 10.1053/he.2000.5746]

48 **Bauer TM**, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Kist M, Blum HE. Diagnosis of small intestinal bacterial overgrowth in patients with cirrhosis of the liver: poor performance of the glucose breath hydrogen test. *J Hepatol* 2000; **33**: 382-386 [PMID: 11019993 DOI: 10.1016/S0168-8278(00)80273-1]

49 **Pande C**, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. *Aliment Pharmacol Ther* 2009; **29**: 1273-1281 [PMID: 19302262 DOI: 10.1111/j.1365-2036.2009.03994.x]

50 **Simrén M**, Stotzer PO. Use and abuse of hydrogen breath tests. *Gut* 2006; **55**: 297-303 [PMID: 16474100 DOI: 10.1136/gut.2005.075127]

51 **Lu H**, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. *Microb Ecol* 2011; **61**: 693-703 [PMID: 21286703 DOI: 10.1007/s00248-010-9801-8]

52 **Zhang Z**, Zhai H, Geng J, Yu R, Ren H, Fan H, Shi P. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. *Am J Gastroenterol* 2013; **108**: 1601-1611 [PMID: 23877352 DOI: 10.1038/ajg.2013.221]

53 **Xu M**, Wang B, Fu Y, Chen Y, Yang F, Lu H, Chen Y, Xu J, Li L. Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease. *Microb Ecol* 2012; **63**: 304-313 [PMID: 21814872 DOI: 10.1007/s00248-011-9925-5]

54 **Wu ZW**, Ling ZX, Lu HF, Zuo J, Sheng JF, Zheng SS, Li LJ. Changes of gut bacteria and immune parameters in liver transplant recipients. *Hepatobiliary Pancreat Dis Int* 2012; **11**: 40-50 [PMID: 22251469 DOI: 10.1016/S1499-3872(11)60124-0]

55 **Zoetendal EG**, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. *Appl Environ Microbiol* 2002; **68**: 3401-3407 [PMID: 12089021 DOI: 10.1128/AEM.68.7.3401-3407.2002]

56 **Bajaj JS**, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. *PLoS One* 2013; **8**: e60042 [PMID: 23565181 DOI: 10.1371/journal.pone.0060042]

57 **Berg RD**, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. *Infect Immun* 1979; **23**: 403-411 [PMID: 154474]

58 **Benten D**, Wiest R. Gut microbiome and intestinal barrier failure--the "Achilles heel" in hepatology? *J Hepatol* 2012; **56**: 1221-1223 [PMID: 22406521 DOI: 10.1016/j.jhep.2012.03.003]

59 **Berg RD**. Bacterial translocation from the gastrointestinal tract. *Trends Microbiol* 1995; **3**: 149-154 [PMID: 7613757 DOI: 10.1016/S0966-842X(00)88906-4]

60 **Cuenca S**, Sanchez E, Santiago A, El Khader I, Panda S, Vidal S, Camilo Nieto J, Juárez C, Sancho F, Guarner F, Soriano G, Guarner C, Manichanh C. Microbiome composition by pyrosequencing in mesenteric lymph nodes of rats with CCl4-induced cirrhosis. *J Innate Immun* 2014; **6**: 263-271 [PMID: 24296725 DOI: 10.1159/000356454]

61 **Steffen EK**, Berg RD, Deitch EA. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. *J Infect Dis* 1988; **157**: 1032-1038 [PMID: 3283254 DOI: 10.1093/infdis/157.5.1032]

62 **Cirera I**, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, Rodés J. Bacterial translocation of enteric organisms in patients with cirrhosis. *J Hepatol* 2001; **34**: 32-37 [PMID: 11211904 DOI: 10.1016/S0168-8278(00)00013-1]

63 **Such J**, Francés R, Muñoz C, Zapater P, Casellas JA, Cifuentes A, Rodríguez-Valera F, Pascual S, Sola-Vera J, Carnicer F, Uceda F, Palazón JM, Pérez-Mateo M. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. *Hepatology* 2002; **36**: 135-141 [PMID: 12085357 DOI: 10.1053/jhep.2002.33715]

64 **Llovet JM**, Bartolí R, March F, Planas R, Viñado B, Cabré E, Arnal J, Coll P, Ausina V, Gassull MA. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. *J Hepatol* 1998; **28**: 307-313 [PMID: 9580278 DOI: 10.1016/0168-8278(88)80018-7]

65 **Pérez-Paramo M**, Muñoz J, Albillos A, Freile I, Portero F, Santos M, Ortiz-Berrocal J. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. *Hepatology* 2000; **31**: 43-48 [PMID: 10613726 DOI: 10.1002/hep.510310109]

66 **Bellot P**, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. *Liver Int* 2013; **33**: 31-39 [PMID: 23121656 DOI: 10.1111/liv.12021]

67 **Francés R**, González-Navajas JM, Zapater P, Muñoz C, Caño R, Pascual S, Santana F, Márquez D, Pérez-Mateo M, Such J. Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. *Clin Exp Immunol* 2007; **150**: 230-237 [PMID: 17822441 DOI: 10.1111/j.1365-2249.2007.03494.x]

68 **Albillos A**, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, Ruiz-del-Arbol L, Alvarez-Mon M. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. *Hepatology* 2003; **37**: 208-217 [PMID: 12500206 DOI: 10.1053/jhep.2003.50038]

69 **Steffen EK**, Berg RD. Relationship between cecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes. *Infect Immun* 1983; **39**: 1252-1259 [PMID: 6341234]

70 **Sánchez E**, Casafont F, Guerra A, de Benito I, Pons-Romero F. Role of intestinal bacterial overgrowth and intestinal motility in bacterial translocation in experimental cirrhosis. *Rev Esp Enferm Dig* 2005; **97**: 805-814 [PMID: 16438624 DOI: 10.4321/S1130-01082005001100005]

71 **Cariello R**, Federico A, Sapone A, Tuccillo C, Scialdone VR, Tiso A, Miranda A, Portincasa P, Carbonara V, Palasciano G, Martorelli L, Esposito P, Cartenì M, Del Vecchio Blanco C, Loguercio C. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. *Dig Liver Dis* 2010; **42**: 200-204 [PMID: 19502117 DOI: 10.1016/j.dld.2009.05.001]

72 **Scarpellini E**, Valenza V, Gabrielli M, Lauritano EC, Perotti G, Merra G, Dal Lago A, Ojetti V, Ainora ME, Santoro M, Ghirlanda G, Gasbarrini A. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? *Am J Gastroenterol* 2010; **105**: 323-327 [PMID: 19844200 DOI: 10.1038/ajg.2009.558]

73 **Kalaitzakis E**, Johansson JE, Bjarnason I, Björnsson E. Intestinal permeability in cirrhotic patients with and without ascites. *Scand J Gastroenterol* 2006; **41**: 326-330 [PMID: 16497621 DOI: 10.1080/00365520510024278]

74 **Sipeki N**, Antal-Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. *World J Gastroenterol* 2014; **20**: 2564-2577 [PMID: 24627592 DOI: 10.3748/wjg.v20.i10.2564]

75 **Purchiaroni F**, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, Ojetti V, Scarpellini E, Gasbarrini A. The role of intestinal microbiota and the immune system. *Eur Rev Med Pharmacol Sci* 2013; **17**: 323-333 [PMID: 23426535]

76 **Teltschik Z**, Wiest R, Beisner J, Nuding S, Hofmann C, Schoelmerich J, Bevins CL, Stange EF, Wehkamp J. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. *Hepatology* 2012; **55**: 1154-1163 [PMID: 22095436 DOI: 10.1002/hep.24789]

77 **Moreau R**, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013; **144**: 1426-137, 1426-137, [PMID: 23474284 DOI: 10.1053/j.gastro.2013.02.042]

78 **Campillo B**, Richardet JP, Kheo T, Dupeyron C. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. *Clin Infect Dis* 2002; **35**: 1-10 [PMID: 12060868 DOI: 10.1086/340617]

79 **Merli M**, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, Ridola L, Attili AF, Venditti M. Cirrhotic patients are at risk for health care-associated bacterial infections. *Clin Gastroenterol Hepatol* 2010; **8**: 979-985 [PMID: 20621200 DOI: 10.1016/j.cgh.2010.06.024]

80 Giannelli V, Di Gregorio V, Lucidi C, Iebba V, Santangelo F, Attili AF, Riggio O, Schippa S, Merli M. Does the gut microbiota modulate the inflammatory state in cirrhotic host? *J Hepatol* 2014; **60**: S41

81 **Schnabl B**, Brenner DA. Interactions between the intestinal microbiome and liver diseases. *Gastroenterology* 2014; **146**: 1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]

82 **Assimakopoulos SF**, Scopa CD, Vagianos CE. Pathophysiology of increased intestinal permeability in obstructive jaundice. *World J Gastroenterol* 2007; **13**: 6458-6464 [PMID: 18161914 DOI: 10.3748/wjg.13.6458]

83 **Runyon BA**, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. *J Hepatol* 1994; **21**: 792-796 [PMID: 7890896 DOI: 10.1016/S0168-8278(94)80241-6]

84 **Yeh DC**, Wu CC, Ho WM, Cheng SB, Lu IY, Liu TJ, P'eng FK. Bacterial translocation after cirrhotic liver resection: a clinical investigation of 181 patients. *J Surg Res* 2003; **111**: 209-214 [PMID: 12850464 DOI: 10.1016/S0022-4804(03)00112-4]

85 **Steib CJ**, Hartmann AC, v Hesler C, Benesic A, Hennenberg M, Bilzer M, Gerbes AL. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. *Lab Invest* 2010; **90**: 1024-1032 [PMID: 20212458 DOI: 10.1038/labinvest.2010.60]

86 **Rasaratnam B**, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. *Ann Intern Med* 2003; **139**: 186-193 [PMID: 12899586 DOI: 10.7326/0003-4819-139-3-200308050-00008]

87 **Zhu Q**, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang ZD, DuPont HL, Shah VH. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. *J Hepatol* 2012; **56**: 893-899 [PMID: 22173161 DOI: 10.1016/j.jhep.2011.11.013]

88 **Tranah TH**, Vijay GK, Ryan JM, Shawcross DL. Systemic inflammation and ammonia in hepatic encephalopathy. *Metab Brain Dis* 2013; **28**: 1-5 [PMID: 23224356 DOI: 10.1007/s11011-012-9370-2]

89 **Sharma P**, Sharma BC. Rifaximin treatment in hepatic encephalopathy. *N Engl J Med* 2010; **362**: 2423-244; author reply 2423-244; [PMID: 20578274 DOI: 10.1056/NEJMc1004719]

90 **Crispe IN**. The liver as a lymphoid organ. *Annu Rev Immunol* 2009; **27**: 147-163 [PMID: 19302037 DOI: 10.1146/annurev.immunol.021908.132629]

91 **Chen GY**, Nuñez G. Sterile inflammation: sensing and reacting to damage. *Nat Rev Immunol* 2010; **10**: 826-837 [PMID: 21088683 DOI: 10.1038/nri2873]

92 **Takeuchi O**, Akira S. Pattern recognition receptors and inflammation. *Cell* 2010; **140**: 805-820 [PMID: 20303872 DOI: 10.1016/j.cell.2010.01.022]

93 **Yamamoto M**, Takeda K. Current views of toll-like receptor signaling pathways. *Gastroenterol Res Pract* 2010; **2010**: 240365 [PMID: 21197425 DOI: 10.1155/2010/240365]

94 **Huang H**, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, Rowland CM, Catanese JJ, Leong DU, Sninsky JJ, Layden TJ, Wright TL, White T, Cheung RC. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. *Hepatology* 2007; **46**: 297-306 [PMID: 17461418 DOI: 10.1002/hep.21695]

95 **Isayama F**, Hines IN, Kremer M, Milton RJ, Byrd CL, Perry AW, McKim SE, Parsons C, Rippe RA, Wheeler MD. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. *Am J Physiol Gastrointest Liver Physiol* 2006; **290**: G1318-G1328 [PMID: 16439470 DOI: 10.1152/ajpgi.00405.2005]

96 **Seki E**, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med* 2007; **13**: 1324-1332 [PMID: 17952090 DOI: 10.1038/nm1663]

97 **Uesugi T**, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. *Hepatology* 2001; **34**: 101-108 [PMID: 11431739 DOI: 10.1053/jhep.2001.25350]

98 **Yin M**, Gäbele E, Wheeler MD, Connor H, Bradford BU, Dikalova A, Rusyn I, Mason R, Thurman RG. Alcohol-induced free radicals in mice: direct toxicants or signaling molecules? *Hepatology* 2001; **34**: 935-942 [PMID: 11679964 DOI: 10.1053/jhep.2001.28888]

99 **Adachi Y**, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. *Gastroenterology* 1995; **108**: 218-224 [PMID: 7806045 DOI: 10.1016/0016-5085(95)90027-6]

100 **Bass NM**, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. *N Engl J Med* 2010; **362**: 1071-1081 [PMID: 20335583 DOI: 10.1056/NEJMoa0907893]

101 **Bergheim I**, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. *J Hepatol* 2008; **48**: 983-992 [PMID: 18395289 DOI: 10.1016/j.jhep.2008.01.035]

102 **Patidar KR**, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. *Metab Brain Dis* 2013; **28**: 307-312 [PMID: 23389621 DOI: 10.1007/s11011-013-9383-5]

103 **Dhiman RK**. Gut microbiota and hepatic encephalopathy. *Metab Brain Dis* 2013; **28**: 321-326 [PMID: 23463489 DOI: 10.1007/s11011-013-9388-0]

104 **Rayes N**, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, Bengmark S, Neuhaus P. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. *Am J Transplant* 2005; **5**: 125-130 [PMID: 15636620 DOI: 10.1111/j.1600-6143.2004.00649.x]

105 **Lata J**, Novotný I, Príbramská V, Juránková J, Fric P, Kroupa R, Stibůrek O. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. *Eur J Gastroenterol Hepatol* 2007; **19**: 1111-1113 [PMID: 17998837 DOI: 10.1097/MEG.0b013e3282efa40e]

106 **Gupta N**, Kumar A, Sharma P, Garg V, Sharma BC, Sarin SK. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. *Liver Int* 2013; **33**: 1148-1157 [PMID: 23601333 DOI: 10.1111/liv.12172]

107 **Bajaj JS**, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. *Am J Gastroenterol* 2008; **103**: 1707-1715 [PMID: 18691193 DOI: 10.1111/j.1572-0241.2008.01861.x]

**P-Reviewer:** Bujanda L, Hahm kb, Ohkohchi N **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**



**Figure 1 bacteria has been recently associated with systemic inflammation and the complications of cirrhosis.**

**Table 1 Changes in intestinal microbiota and clinical consequence in cirrhosis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Ref.** | **Implicated dysbiosis** | **Potential biological functions** |
| Cirrhosis *vs* healthy people  | Stool samples, Bajaj *et al*[5] | Overgrowth of (family):  | There is a reduction in autochthonous taxa that can be disruptive given that they produce short-chain fatty acids that reduce colonic bacteria improve the intestinal barrier. |
|  Leuconostocaceae ↑ |
|  **Enterobacteriaceae** ↑↑↑ |
|  Fusobacteriaceae ↑ |  |
|  Alcaligenaceae ↑ |  |
| Reduction of (family): |
|  **Clostridium Incertae sedis XIV** ↓↓↓ |
|  Lachnospiraceae ↓ |  |
|  Ruminococcaceae ↓ |  |
| Mucosal samples, Bajaj *et al[*5] | Overgrowth of (family - genus):  | There was a significantly lower abundance of autochthonous genera (Clostridium Incertae Sedis XIV) and a higher abundance of potentially pathogenic ones (Enterococcus, Proteus, Clostridium) in cirrhotic patients compared with controls’mucosa. |
|  Clostridiaceae - Clostridium ↑ |
|  **Enterococcaceae - Enterococcus** ↑↑ |
|  Enterobacteriaceae - Proteus ↑ |
| Reduction of (family - genus): |
|  **Clostridium Incertae sedis XIV** ↓↓ |
|  Ruminococcaceae - Subdoligranulum ↓ |
|  Lachnospiraceae ↓ |  |
| Cirrhotics with *vs* without infection | Stool samples, Bajaj *et al*[18] | Overgrowth of (family):  | There is an increase in abundance of pathogenic taxa, reduction in autochthonous taxa and higher endotoxemia compared to uninfected patients despite matching for MELD-score and medication confounders. |
|  Enterobacteriaceae ↑ |
| Reduction of (family): |
|  Clostridium Incertae sedis XIV ↓↓ |
|  Lachnospiraceae ↓↓ |
|  Ruminococcaeae ↓↓ |
|  Veillonellaceae ↓ |  |
| Cirrhotics with *vs* without inflammation | Stool samples, Bajaj *et al*[18] | Overgrowth of (family):  | This relative overgrowth of Enterobacteriaceae can result in endotoxemia due to increased production with worsening intestinal permeability, which has been associated with worsening disease severity and complications in cirrhosis. The lower abundance of butiyrate producing genera (such as Roseburia and Ruminococcaceae) might rapresents a trophic injury to cololnicytes. |
|  Bacteroidaceae |  |
|  Enterobacteriaceae |  |
| Reduction of (family): |
|  Clostridium Incertae sedis XIV  |
|  Lachnospiraceae  |  |
|  Ruminococcaeae  |  |
|  Roseburia |  |
| Cirrhotics with *vs* without hepatic hencephalopathy | Mucosal samples, Bajaj *et al*[23] | Overgrowth of (family - genus):  | Firmicutes such as members of genera Veillonella, Megasphaera, Bifidobacterium, and Enterococcus were higher in HE whereas Roseburia was more abundant in the no-HE group. |
|  Enterococcaceae - Enterococcus ↑ |
|  Veillonellaceae - Megasphaera ↑ |
|  **Bifidobacteriaceae - Bifidobacterium** ↑↑ |
|  Veillonellaceae - Veillonella ↑ |
| Reduction of (family - genus): |
|  **Lachnospiraceae - Roseburia** ↓↓ |
| Higher MELD score  | Stool samples, Bajaj *et al*[18] | Overgrowth of (family):  | With the increase in cirrhosis severity, there was a significant increase in potentially pathogenic and decrease in autochthonous taxa. |
|  Staphylococcae |  |
|  Enterococceae |  |
|  Enterobacteriaceae |  |
| Reduction of (family): |
|  Clostridium Incertae sedis XIV  |
|  Lachnospiraceae  |  |
|  Ruminococcaeae  |  |
|  Rikenellaceae |  |
| Cirrhotics with *vs* without decompensated disease | Stool samples, Bajaj *et al*[18] | Overgrowth of (family):  | With the increase in cirrhosis severity, there was a significant increase in potentially pathogenic and decrease in autochthonous taxa. |
|  Enterobacteriaceae ↑ |
|  Alcaligenaceae ↑ |  |
| Reduction of (family): |
|  Clostridium Incertae sedis XIV ↓ |
|  Lachnospiraceae ↓ |  |
|  Ruminococcaeae ↓ |  |
|  Veillonellaceae ↓ |  |
| Aetiology of cirrhosis | Alcoholic aetiology *vs* others | Stool samples, Bajaj *et al*[18] | Overgrowth of (family):  | Alcoholic cirrhotics had a significantly higher abundance of Enterobacteriaceae and Halomonadaceae, lower Lachnospiraceae, Ruminococcaceae, and Clostridialies XIV, despite statistically similar MELD score and BMI compared to those without alcoholic etiology. |
|  Enterobacteriaceae ↑ |  |
|  Halomonadaeace ↑ |  |
| Reduction of (family): |
|  Clostridiales Incertae sedis XIV ↓ |
|  Lachnospiraceae ↓ |  |
|  Ruminococcaceae ↓ |
| NASH aetiology *vs* others | Overgrowth of (family):  | There is a higher abundance of Porphyromonadaceae, Bacterioidaceae, and lower Veillonellaceae in NASH patients than the non-NASH counterparts. |
|  |  Bacteroidaceae ↑ |  |
|  |  Porphyromonadaceae ↑ |
|  | Reduction of (family): |
|  |  Veillonellaceae ↓ |  |

Normalized relative abundance: ↑/↓: 1-2 fold of increase/reduction *vs* control;↑ ↑/↓ ↓: 3-6 fold of increase/reduction vs control; ↑ ↑ ↑/ ↓ ↓ ↓ > 7 fold of increasereduction *vs* control. NASH: Nonalcoholic steatohepatitis; MELD score: Model for end-stage liver disease score; BMI: Body mass index.

**Table 2 Effects of the intervention on gut microbiota composition and its clinical and/or biochemical consequences**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study** | **Category of patients** | **Therapy** | **Clinical outcome** | **Microbiota changing** |
| Albillos *et al*[68] | RCT | 102 Cirrhotics/30 controls  | Norfloxacin 400mg orally TD *vs* Placebo | norfloxacinimproved cardiac index in patients with elevated LBP, no improvement in portal pressure in the rest of patients | NA |
| Bass *et al*[100] | RCT | 299 cirrhotics | Rifaximin 550 mg twice daily (140 patients) *vs* placebo (159 patients)  | Rifaximin group maintained remission from hepaticencephalopathy more effectively than did placebo.  | NA |
| Rayes *et al*[104] | RCT | 66 cirrhotics underwent LT | Pediacoccuspentosaceus + Leuconostoc mesenteroides + Lactobacillus paracasei and L. plantarum *vs* Placebo | Significant reduction of post-operative bacterial infections(3% *vs* 48% of controlls)  | NA |
| Lata *et al*[105] | RCT | 39 cirrhotics | Cirrhotics were randomly allocated to treatment with E. coli Nissle or placebo for 42 d | Authors found a trend of significant lowering of the endotoxemia (*P =* 0.07) and improvement of Child-Pugh score (*P =* 0.06) | Restoration of normal colonic colonization in pts treated with E.coli Nissle |
| Gupta *et al*[106] | RCT | 94 cirrhotic patients with large oesophageal variceswithout history of variceal bleeding  | Patients were randomized to three treatmentGroups: (1) propranolol plus placebo (2) propranololPlus norfloxacin 400 mg BD(3) propranolol plusVSL#3, 900 billion/d | Group 2 and 3 showed a greater reduction in HVPG than Group 1. In addition, in Group 2 and 3 theTNF-a levels were significantly lower than Group 1 | NA |
| Bajaj *et al*[107] | RCT | 25 nonalcoholic MHE cirrhotics (defined by a standard psychometric battery)  | Cirrhotics were randomized toReceive yogurt contained Lactobacillus bulgaricus and StreptococcusThermophilus or no treatment for 60 d in a 2:1 ratio. | Twelve of 17 yogurt patients reversed MHE(71% on intention-to-treat and 86% on per-protocol analysis)compared to 0% in the no-treatment group (*P* =0.0030)Levels of citokyne were similar between groups  | NA |
| Bajaj *et al*[56] | PS | 20 nonalcoholic MHE cirrhotics (defined by a standard psychometric battery) | Patients received rifaximin 550 mg BID for 8 weeks and the psychometric tests, stool analysis and blood test were repeated at the end of the study | There was a significant improvement in cognition test performance and a reduction of endotoxemiaafter rifaximin. | After rifaximin there was a significant reduction in the abundance of faecal Veillonellaceae(*p* = 0.025) and increase in the abundance of Eubacteriaceae(*p* = 0.042)  |
| Bergheim *et al*[101] | animal model | Mice with induced NAFLD | For 8 wk, C57BL/ J6 mice had free access to solutions containing 30% glucose, fructose, sucrose, or water sweetened with artificial sweetener or plain water | The group treated with polymixin B and Neomycin were protected against the fructose-induced NAFLD and had a lower level of endotoxin | NA |

RCT: Randomized controlled study; PS: Pilot study ; LT: Liver translanted; NA: Not applicable (the study did not provide microbiota characterization); BD: Bis in die; HVPG: Hepatic venus pressure gradient.